CFF-Championed Bill Eliminates Barriers to Participation in Clinical Trials for People with CF and other Rare Diseases
Site Search
Legislation Includes Measures to Increase Patient and Expert Participation in FDA Review of Rare Disease Drugs
Las personas con fibrosis quística y sus familias se han enfrentado a importantes cargas económicas debido a los programas acumuladores de copago. Familiarícese con estos programas y lo que implican para usted y sus seres queridos.
People with cystic fibrosis and their families have faced significant cost burdens due to copay accumulator programs. Get caught up on these programs and what they mean for you and your loved ones.
With promising new discoveries in the pipeline and advancements we've made in the search for new treatments and a cure, we must continue our work to protect access to adequate, affordable insurance that preserves access to high-quality cystic fibrosis care; and support progress toward new therapies and a cure.
Robust funding for the National Institutes of Health helps ensure innovation in basic research and a full pipeline of cystic fibrosis therapies. A well-resourced U.S. Food and Drug Administration helps advance therapies that are safe and effective.
In a complex and rapidly changing health care system, we support policies that promote adequate, affordable health coverage so people living with cystic fibrosis can receive the high-quality, specialized care they need to live longer, healthier lives.